Cara Therapeutics Share Price Today
(NASDAQ: CARA)

Name: Cara Therapeutics Share Price Today (NASDAQ: CARA) - Cara Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Cara Therapeutics share price is $4.5 & ₹391.36 as on 6 Mar 2025, 2.30 'hrs' IST

$4.5

▲

0.07

(1.58%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Cara Therapeutics share price in Dollar and Rupees. Guide to invest in Cara Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cara Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Cara Therapeutics share price movements

Today's Low: $4.36
Today's High: $4.66
$4.50
3.22%
Downside
Day's Volatility :6.55%
Upside
3.43%
52 Weeks Low: $2.71
52 Weeks High: $13.20
$4.50
39.81%
Downside
52 Weeks Volatility :79.48%
Upside
65.91%

Cara Therapeutics (CARA) Returns

Period	Cara Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	37.08%	2.1%	0.0%
6 Months	15.01%	-4.1%	0.0%
1 Year	-62.71%	2.2%	0.0%
3 Years	-96.5%	11.8%	-11.6%

Cara Therapeutics (CARA) Key Statistics

in dollars & INR

Previous Close	$4.43
Open	$4.3
Today's High	$4.66
Today's Low	$4.355
Market Capitalization	$21.5M
Today's Volume	$1.6K
52 Week High	$13.2
52 Week Low	$2.7084
Revenue TTM	$8.7M
EBITDA	$-82.1M
Earnings Per Share (EPS)	$-20.65
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-221.25%

How to invest in Cara Therapeutics Stock (CARA) from India?

It is very easy for Indian residents to invest directly in Cara Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cara Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cara Therapeutics or CARA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cara Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cara Therapeutics shares which would translate to 0.193 fractional shares of Cara Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cara Therapeutics, in just a few clicks!

Returns in Cara Therapeutics (CARA) for Indian investors in Rupees

The Cara Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Cara Therapeutics investment value today

Current value as on today

₹42,842

Returns

₹57,158

(-57.16%)

Returns from Cara Therapeutics Stock

₹62,121 (-62.12%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Cara Therapeutics (CARA)

-70%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Cara Therapeutics Stock from India on INDmoney has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cara Therapeutics

Vanguard Group Inc
0.31%
Rockefeller Capital Management L.P.
0.28%
Farallon Capital Management, L.L.C.
0.24%
Susquehanna International Group, LLP
0.21%
Renaissance Technologies Corp
0.17%
Shay Capital LLC
0.16%

Analyst Recommendation on Cara Therapeutics

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Cara Therapeutics(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cara Therapeutics Stock (CARA)

What analysts predicted

Upside of 166.67%

Target:

$12.00

Current:

$4.50

Insights on Cara Therapeutics Stock (Ticker Symbol: CARA)

Price Movement
In the last 3 months, CARA stock has moved up by 37.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 991.0K → 2.55M (in $), with an average increase of 61.2% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -32.33M → -12.47M (in $), with an average increase of 39.7% per quarter
CARA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 121.7%
CARA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 144.2%
Price to Sales
ForCARA every $1 of sales, investors are willing to pay $2.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

CARA Cara Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$13.5M	↑ 1378.49%
Net Income	$-74.0M	↑ 27.33%
Net Profit Margin	-549.51%	↑ 5830.84%

	FY19	Y/Y Change
Revenue	$19.9M	↑ 47.64%
Net Income	$-106.4M	↑ 43.72%
Net Profit Margin	-534.91%	↑ 14.6%

	FY20	Y/Y Change
Revenue	$135.1M	↑ 579.28%
Net Income	$8.4M	↓ 107.91%
Net Profit Margin	6.23%	↑ 541.14%

	FY21	Y/Y Change
Revenue	$23.0M	↓ 82.95%
Net Income	$-88.2M	↓ 1148.67%
Net Profit Margin	-382.98%	↓ 389.21%

	FY22	Y/Y Change
Revenue	$41.9M	↑ 81.81%
Net Income	$-83.4M	↓ 5.42%
Net Profit Margin	-199.23%	↑ 183.75%

	FY23	Y/Y Change
Revenue	$21.0M	↓ 49.92%
Net Income	$-118.5M	↑ 42.08%
Net Profit Margin	-565.21%	↓ 365.98%

	Q2 FY23	Q/Q Change
Revenue	$6.9M	↑ 12.46%
Net Income	$-31.5M	↑ 22.58%
Net Profit Margin	-454.05%	↓ 37.5%

	Q3 FY23	Q/Q Change
Revenue	$4.9M	↓ 29.81%
Net Income	$-28.0M	↓ 10.95%
Net Profit Margin	-576.08%	↓ 122.03%

	Q4 FY23	Q/Q Change
Revenue	$3.0M	↓ 38.27%
Net Income	$-32.3M	↑ 15.36%
Net Profit Margin	-1.1K%	↓ 500.38%

	Q1 FY24	Q/Q Change
Revenue	$2.1M	↓ 28.93%
Net Income	$-30.7M	↓ 5.07%
Net Profit Margin	-1.4K%	↓ 361.29%

	Q2 FY24	Q/Q Change
Revenue	$991.0K	↓ 53.58%
Net Income	$-20.0M	↓ 34.79%
Net Profit Margin	-2.0K%	↓ 582.03%

	Q3 FY24	Q/Q Change
Revenue	$2.6M	↑ 157.92%
Net Income	$-12.5M	↓ 37.67%
Net Profit Margin	-488.11%	↑ 1531.67%

	FY18	Y/Y Change
Profit	$13.5M	↑ 1378.49%

	FY19	Y/Y Change
Profit	$19.9M	↑ 47.64%

	FY20	Y/Y Change
Profit	$28.0M	↑ 40.86%

	FY21	Y/Y Change
Profit	$23.0M	↓ 17.79%

	FY22	Y/Y Change
Profit	$34.6M	↑ 50.26%

	FY23	Y/Y Change
Profit	$14.8M	↓ 57.24%

	Q2 FY23	Q/Q Change
Profit	$5.5M	↑ 54.27%

	Q3 FY23	Q/Q Change
Profit	$3.3M	↓ 40.02%

	Q4 FY23	Q/Q Change
Profit	$2.3M	↓ 30.05%

	Q1 FY24	Q/Q Change
Profit	$1.5M	↓ 36.34%

	Q2 FY24	Q/Q Change
Profit	$991.0K	↓ 32.72%

	Q3 FY24	Q/Q Change
Profit	$2.6M	↑ 157.92%

	FY18	Y/Y Change
Operating Cash Flow	$-22.3M	↓ 59.32%
Investing Cash Flow	$-82.8M	↑ 131.34%
Financing Cash Flow	$110.8M	↑ 26.03%

	FY19	Y/Y Change
Operating Cash Flow	$-109.2M	↑ 389.78%
Investing Cash Flow	$-30.5M	↓ 63.15%
Financing Cash Flow	$142.6M	↑ 28.69%

	FY20	Y/Y Change
Operating Cash Flow	$-5.5M	↓ 94.98%
Investing Cash Flow	$-20.3M	↓ 33.56%
Financing Cash Flow	$39.1M	↓ 72.55%

	FY21	Y/Y Change
Operating Cash Flow	$-60.1M	↑ 995.08%
Investing Cash Flow	$-4.8M	↓ 76.57%
Financing Cash Flow	$46.6M	↑ 19.08%

	FY22	Y/Y Change
Operating Cash Flow	$-78.7M	↑ 31.03%
Investing Cash Flow	$128.7M	↓ 2809.05%
Financing Cash Flow	$311.0K	↓ 99.33%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-20.4M	↓ 40.94%
Investing Cash Flow	$32.8M	↑ 85.24%
Financing Cash Flow	$1.1M	↑ 99.29%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 3.91%
Investing Cash Flow	$23.2M	↓ 29.41%
Financing Cash Flow	$1.1M	↑ 0.0%

Cara Therapeutics Technicals Summary

Sell

Neutral

Buy

Cara Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cara Therapeutics (CARA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cara Therapeutics Inc	-7.32%	15.01%	-62.71%	-96.5%	-97.33%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cara Therapeutics Inc	NA	NA	0.0	0.0	-2.21	-0.62	NA	0.16
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cara Therapeutics Inc	Buy	$21.5M	-97.33%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Cara Therapeutics

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Organization	Cara Therapeutics
Employees	55
CEO	Mr. Christopher A. Posner
Industry	Health Technology

Management People of Cara Therapeutics

Name	Title
Mr. Christopher A. Posner	President, CEO & Director
Mr. Ryan D. Maynard	Chief Financial Officer
Mr. Scott M. Terrillion J.D.	Chief Compliance Officer, General Counsel & Corporate Secretary
Mr. Matthew Murphy	Manager of Investor Relations

Important FAQs about investing in CARA Stock from India :

What is Cara Therapeutics share price today?

Cara Therapeutics share price today stands at $4.50, Open: $4.30 ; Previous Close: $4.43 ; High: $4.66 ; Low: $4.36 ; 52 Week High: $13.20 ; 52 Week Low: $2.71.

The stock opens at $4.30, after a previous close of $4.43. The stock reached a daily high of $4.66 and a low of $4.36, with a 52-week high of $13.20 and a 52-week low of $2.71.

Can Indians buy Cara Therapeutics shares?

Yes, Indians can invest in the Cara Therapeutics (CARA) from India.

With INDmoney, you can buy Cara Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cara Therapeutics at zero transaction cost.

How can I buy Cara Therapeutics shares from India?

It is very easy to buy Cara Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cara Therapeutics (CARA) be purchased?

Yes, you can buy fractional shares of Cara Therapeutics with INDmoney app.

What are the documents required to start investing in Cara Therapeutics stocks?

To start investing in Cara Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.